Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD)

Abstract

Background

The European Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (EUROSTAD) is an ongoing observational study aiming to describe characteristics of patients with atopic dermatitis (AD) treated with systemic therapy over time and the management of their disease in a real-world setting.

Methods

Data from patients enrolled in EUROSTAD between March 2017 and April 2019 were analyzed for systemic therapy use and treatment change over 12 months.

Results

288 patients reported taking systemic medications; 42.7% received cyclosporine, 35.3% dupilumab, 28.1% methotrexate, 25.4% oral corticosteroids, 6.8% azathioprine, 6.1% injectable corticosteroids, and 3.4% mycophenolate. The median duration of treatment was 1.1 months for oral systemic corticosteroids, 3.2 months for injectable corticosteroids, 4.8 months for cyclosporine, 7.3 months for methotrexate, and 14.9 months for dupilumab. The most frequent reasons for stopping treatment included lack of efficacy, patient decision, adverse events, and disease well controlled.

Conclusion

The 12-month interim EUROSTAD study analysis highlights the current trends and outcomes of systemic treatments for moderate-to-severe AD. Among all systemic treatments for AD, dupilumab was the least likely to be discontinued, whereas cyclosporine and corticosteroids, whilst effective, were primarily limited to episodic flare management consistent with treatment guidelines.

Video Abstract

Read the transcript

Watch the video on Vimeo

© 2022 Sanofi. Published with license by Taylor & Francis Group, LLC.

Keywords:

• Real-world data
• dupilumab
• treatment effectiveness
• atopic dermatitis

Acknowledgments

Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. Medical writing/editorial assistance was provided by Yunyu Huang, Ph.D. of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. according to the Good Publication Practice guideline.

Author contribution

MdBW, MA contributed to study concept and design, analysis, and interpretation, provided critical feedback on the manuscript, approved the final manuscript for submission, and were accountable for the accuracy and integrity of the manuscript. SJ conducted statistical analyses on the data. All authors interpreted the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and were accountable for the accuracy and integrity of the manuscript.

Disclosure statement

MdBW is a consultant, advisory board member, and/or speaker for AbbVie, Almirall, Aslan Pharmaceuticals, Eli Lilly, Galderma, Janssen, LEO Pharma, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, and UCB. AEP is an advisory board member, speaker or investigator for AbbVie, Almirall, Bristol Myers Squibb, Eli Lilly, La Roche-Posay, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB. SMF is a speaker and consultant for Drex Pharma, Menarini, Novartis, Pierre Fabre Laboratories, Sanofi Genzyme, and SVR; Principal Investigator for Eli Lilly, Novartis, Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme. AP is an advisory board member, investigator for, and received grants from Eli Lilly; advisory board member, and/or investigator, and/or speaker for, and/or has received grants from AbbVie; and advisory board member for and received grants from Almirall, Eli Lilly, La Roche-Posay, LEO Pharma, Menarini, Novartis, Pierre Fabre, Roche, Sanofi Genzyme, Pfizer, and UCB. AS is a Principal Investigator for Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. MLS is an advisory board member and consultant for Sanofi Genzyme; investigator for AbbVie, Novartis, and Sanofi Genzyme; and consultant for Regeneron Pharmaceuticals, Inc. MT is an investigator, speaker, and consultant for Regeneron Pharmaceuticals, Inc. and/or Sanofi Genzyme; investigator, speaker and consultant for AbbVie; investigator and consultant for Lilly; consultant for Medac. MA is an employee and shareholder for Regeneron Pharmaceuticals, Inc. SJ and MD are employees of Sanofi Genzyme and may hold stock and/or stock options in the company.

Additional information

Funding

Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. Medical writing/editorial assistance was provided by Yunyu Huang of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.